M

odern medicine achieved some amazing things in the 20th century. Antibiotics and vaccines were hailed as triumphs for humanity, and no one much worried about the cost.

That’s not the case anymore. Today, one of the big debates in medicine revolves around how much we’re willing to pay for a new generation of cures.

In this latest episode of the Signal podcast, we focus in on hepatitis C, a chronic viral infection of the liver that affects at least 130 million people worldwide. New drugs that cure hep C emerged in recent years, but they’re pricey — as much as $94,500 for a course of treatment.

advertisement

That price tag has sparked a big debate. Listen in as we dissect it.

Subscribe to Signal on iTunes or Stitcher. Catch our previous episodes here as well.

The Signal podcast is produced by Katie Hiler.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Signal: P Value
Signal Podcast
Signal: Golden Ticket Funding
Signal Podcast
Signal: Episode
Signal Podcast

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.

X